Human medicines European public assessment report (EPAR): Trixeo Aerosphere, formoterol,glycopyrronium bromide,budesonide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 09/12/2020, Revision: 4, Status: Authorised
Trixeo Aerosphere is a medicine used to treat patients with moderate to severe chronic obstructive pulmonary disease (COPD), a long-term disease in which the airways and air sacs in the lungs become damaged or blocked, leading to difficulty breathing.
Trixeo Aerosphere is used for maintenance (regular) treatment in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a long-acting muscarinic antagonist.
Trixeo Aerosphere contains the active substances formoterol, glycopyrronium bromide and budesonide.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
